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Abstract 
Background: The aim of this study was to determine the prevalence of CSF and VEP 
abnormalities, and ANA titers in patients with either clinically or radiologically isolated 
syndrome (CIS and RIS).  
Patients and methods: We gathered records from 330 hospitalized patients diagnosed 
with CIS/RIS within a three year period. Symptoms, CSF findings, VEP and ANA titers 
were analyzed. 
Results: Incomplete transverse myelitis was the presenting symptom in 32.7%, optic 
neuritis in 22.7%, brainstem/cerebellar symptoms in 19.4%, hemispheral symptoms in 
2.7% and multifocal symptoms in 15.2% of patients in the CIS cohort. We identified 24 
(7.3%) patients with atypical or no symptoms – RIS cohort. Positive OCB were found in 
75.5% patients. When we divided the patients into CIS and RIS groups the presence of 
OCB was 82.4% and 44% respectively. VEP was performed in 87.3% patients and 
prolonged latencies were found in 39.6% of them (43.8% and 14.3% in the CIS and RIS 
cohort, respectively). ANA were positive in 15.2% (14.7% and 16% in the CIS and RIS 
cohort, respectively) of patients. RIS patients had statistically significant lower 
percentages of positive OCB and positive VEP (p= 0,002 and 0.001, respectively). 
Conclusion: Detection of OCB and VEP still has an important role for satisfying the „no 
better explanation for the clinical presentation“ criteria when presented with a patient 
with a first “radiological” demyelinating episode. 
 
Key words: clinically isolated syndrome, radiologically isolated syndrome, oligoclonal 
bands, visual evoked potentials 
 3
Introduction 
 
An acute or subacute episode of neurologic deficit which is known as a clinically isolated 
syndrome (CIS) is a presenting syndrome in 85% of patients who will ultimately develop 
multiple sclerosis (MS). Most of these patients present with optic neuritis, transverse 
myelitis or brainstem/cerebellar symptoms, although a substantial number have 
multifocal symptoms (1). Another group of patients are those who are asymptomatic or 
present with atypical symptoms – the radiologically isolated syndrome (RIS). The 
diagnostic cornerstone in the diagnosis of CIS is brain magnetic resonance imaging 
(MRI), the importance of which is reemphasized in the 2010 revision of McDonald’s 
criteria (2). Nevertheless, there are other significant paraclinical investigations aiding in 
the diagnosis of MS that include cerebrospinal fluid analysis (CSF) and visual evoked 
potentials (VEP) (3). The 2010 revised McDonald criteria have altered the place of  
CSF analysis and VEP in relapsing cases. Despite of this, they still have an important role 
for satisfying the „no better explanation for the clinical presentation“ criteria. 
CSF analysis is an important diagnostic tool when presented with a patient displaying a 
CIS suggestive of MS. Presence of IgG oligoclonal bands (OCB) has been a part of the 
original Poser's diagnostic criteria for MS (4). Although CSF analysis is no longer 
necessary for establishing the diagnosis of relapsing remitting multiple sclerosis, it is of 
great importance in patients with an atypical clinical presentation and necessary for 
exclusion of infectious and inflammatory MS imitators (2,5). While the prognostic value 
of OCB is still a matter of debate, it remains the most useful CSF biomarker for MS (6). 
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VEP typically shows prolonged latencies in two thirds of patients with relapsing 
remitting MS but only in one third of CIS patients, although results differ between reports 
(7,8).  
Antinuclear antibiodies (ANA) are used as a screening tool for possible “collagen 
vascular” MS imitators such as systemic lupus erythematosus (SLE). Nevertheless, a 
substantial number of CIS patients will have positive ANA without any signs of SLE (9). 
In MS patients on the other hand, a correlation between ANA and MS disease activity 
was observed in one study (10). 
The aim of this study was to determine the prevalence of CSF and VEP abnormalities, 
and ANA titers in patients with either clinically or radiologically isolated syndrome.  
 
Patients and methods  
We gathered records from all patients who were hospitalized in our Referral Centre 
between 2008 to 2010 due to a suspected first demyelinating event. All patients who 
underwent CSF analysis for OCB, had VEP performed and ANA titers done were 
included in the study.  
All tests were performed in the same laboratory using standardized methods suggested by 
the manufacturer. OCB detection was performed by isoelectric focusing followed by 
immunoblotting. The interpretation of findings was performed according to the 
Committee of the European Concerted Action for Multiple Sclerosis (Charcot 
Foundation) on CSF analytical standards in the diagnosis of multiple sclerosis (11). Five 
patterns of separation of CSF and serum proteins were identified: type 1 = no OCB in 
CSF and serum, type 2 = two or more OCB present in CSF but none in the serum, type 3 
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= two or more OCB present in CSF and irregularly spaced OCB in serum (the ″ mixed 
pattern ″), type 4 =  irregularly spaced OCB both in CSF and serum (the ″mirror 
pattern″), type 5 = OCB present in both CSF and serum including several regularly 
spaced bands characteristic of monoclonal M protein.  
We have performed statistical analysis to identify the percentage of patients with 
pathological CSF cell counts, CSF protein levels, presence of OCBs, prolonged latencies 
on VEP, and ANA positivity within each group of patients (Table 2). Groups were 
composed of patients with their presenting symptoms as follows: group 1 – transverse 
myelitis, group 2 – optic neuritis, group 3 -  brainstem/cerebellar lesions, group 4 - 
hemispheral symptoms, group 5 - RIS, group 6 - multifocal. The significance of the 
differences between the groups was analyzed by one way analysis of variance (ANOVA). 
If the difference between groups was significant, post hoc analysis using Tukey HSD for 
homogenous distribution and Games-Howell test for non homogenous distribution were 
used. P levels of <0.05 were considered as significant. Statistical analysis was performed 
using SPSS 19.0 (Chicago, IL) statistical software.  
 
Results 
In the three year period we identified 330 patients who were admitted because of the first 
demyelinating event. All studied patients had at least two demyelinating lesions on the 
MRI which were suggestive of MS. 
Transverse myelitis (TM) was the presenting symptom in 108 (32.7%) patients, 75 
(22.7%) patients presented with optic neuritis (ON) and 64 (19.4%) with brainstem 
lesions. Hemispheral symptoms were the presenting symptom in 9 (2.7%) patients. We 
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identified 24 (7.3%) patients who were either asymptomatic at presentation or presented 
with symptoms atypical for MS but had typical demyelinating lesions on MRI. They were 
diagnosed as CIS type 5 – RIS. Detailed clinical presentation, CSF and VEP findings are 
presented in Table 1. The rest of the patients (50 or 15.2%) had multifocal deficits. 
Positive OCB were found in 249 (75.5%) patients. CSF pattern type 1 was found in 71 
patients (21.5%), type 2 in 219 patients (66.4%), type 3 in 30 patients (9.1%), type 4 in 8 
(2.4%) and in 2 (0.6%) patients type 5. Pleocytosis in CSF (defined as more than 5 cells 
per cubic milliliter) was found in 129 (39.1%) of patients, ranging from 6 to 130 cells per 
cubic milliter. Elevated levels of CSF proteins from 0.38 to 1.35 grams per liter (g/l) were 
found in 194 (58.8%) patients, with the normal range being 0.17 – 0.37 g/l. 
When we divided the patients into CIS and RIS groups the presence of OCB was 82.4% 
and 44% respectively.  
VEP was performed in 87.3% patients and prolonged latencies were found in 39.6% of 
them (43.8% and 14.3% in the CIS and RIS cohort, respectively). ANA were positive in 
15.2% (14.7% and 16% in the CIS and RIS cohort, respectively) of patients.  
Difference between groups regarding CSF cell count, CSF protein level, presence of 
OCB, prolonged latencies on VEP and ANA positivity are presented in Table 2. 
 
Discussion 
This study has shown that RIS patients have statistically significant lower percentage of 
positive OCB and positive VEP compared to patients with CIS. Most of the patients in 
our cohort (74.8%) presented with symptoms from the classical triad of CIS – optic 
neuritis, incomplete transverse myelitis and brainstem/cerebellar lesion, making our 
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results concurrent with other reports (1). In patients presenting with such symptoms 
suspicion of MS should be high and the diagnosis more straightforward. Another issue is 
with patients who present as RIS. Such patients pose a greater diagnostic challenge as 
data on the value of OCB detection and VEP analysis in RIS patients are still lacking.  
OCB detection is a valuable diagnostic aid for corroborating MRI findings and 
substantiates clinical suspicion of MS. On the other hand, VEP is useful, not only as a 
diagnostic tool for optic neuritis, but also as a detection method for subclinical lesions of 
the optic nerves. These two paraclinical methods combined with MRI contribute to 
assessment of the risk of CIS patients to develope MS.  
Presence of OCB in patients with CIS varies between groups with reports ranging from 
59 to over 80% (12,13). We have found positive OCB (type 2 and 3) in 75.5 % of all 
patients. Patients with positive OCB are regarded to be at a higher risk of conversion to 
clinically definite MS (CDMS) in a shorter period of time (13,14). OCB are reported to 
be positive in 95% of patients of with CDMS, significantly higher than in CIS patients 
(15). This difference could be explained by a greater disease activity in CDMS as OCB 
are in fact a product of inflammation. Given this, negative OCB has been associated with 
a more favorable prognosis, although further studies are warranted to support these 
findings (5). We found statistically significant less OCB positive RIS patients (44%) than 
patients who presented with the typical MS group of symptoms - TM, ON, brainstem (up 
to 82.4%). The presence of OCB in RIS varies from 30-61.4% (16,17), which together 
with our results argues that RIS patients have lower chance of having positive OCB. 
About one third of RIS patients will go on to develop CIS and OCB have been associated 
with an increased risk when associated with high lesion load on MRI (18). Given the fact 
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that OCB represent inflammatory activity such an association is comprehensible. These 
findings of a growing percentage of positive OCB with the disease progression, suggest a 
continuum from RIS over CIS to clinically definite MS. 
A stronger affinity is found between abnormal VEP findings and clinical conversion of 
RIS patients (18). Abnormal VEP was found in 14.3% of our RIS group. A recent study 
indicated that VEP shows prolonged latencies proportionally more in CDMS and even 
more in secondary progressive MS (8). As the disease progresses in time, it also 
progresses in space, affecting various sites in the central nervous system and frequently 
impairing the brainstem. Although VEP is not specific for MS it is very useful in 
affirming the diagnosis in CIS patients and identifying RIS patients that are at higher risk 
for clinical conversion. 
This study has several limitations; this was observational, retrospective study with a 
referral bias, because all patients came from tertiary center specialized in MS. CIS 
patients are often stratified for risk for MS based on imaging findings. All patients in this 
study had demyelinating lesions on the brain MRI; however we did not correlate the MRI 
results with CSF, VEP and ANA titers. Other two shortcomings are that the study relied 
on the documentation of clinical symptoms in the patients' charts and the lack of follow-
up data.   
However our study gives a direct comparison between CIS and RIS patients on a large 
cohort. 
 
Conclusion 
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In conclusion, we have found that RIS patients have lower chance of having positive 
paraclinical MS criteria (CSF and VEP findings) comparing to patients with CIS. Never 
the less, detection of OCB and VEP still has an important role for satisfying the „no 
better explanation for the clinical presentation“ criteria when presented with a patient 
with a first “radiological” demyelinating episode.  
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Tables 
Table 1. Overview of RIS patients - their age, sex, symptoms and CSF, VEP and ANA 
findings.  
Pt. 
No 
Sex Age Symptoms CSF VEP ANA 
Cell 
count 
Protein OCB 
1 F 25 Headache 2 0.26 N N N 
2 F 29 Headache 3 0.60 P ND N 
3 F 41 Headache 7 0.72 N N N 
4 M 42 Headache 7 0.56 N N P 
5 M 40 Panic attacks 6 0.51 N N N 
6 F 38 Headache, Panick attacks 3 0.50 P ND N 
7 F 44 Headache 11 0.49 P N N 
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8 M 17 Uveitis 10 0.47 P ND N 
9 F 17 Headache 10 0.45 N N N 
10 F 46 Headache, transient 
blurring of vision 
4 0.43 N N N 
11 F 44 Jaw pain 1 0.43 N N N 
12 F 52 Fatigue 4 0.41 N N N 
13 M 29 Pain in the right temple 24 0.40 P N N 
14 F 51 Fatigue, pain in the neck 1 0.40 N N N 
15 F 22 Transitory ischemic attack 7 0.53 P N N 
16 M 28 Headache 3 0.24 N N N 
17 F 36 Epilepsy 12 0.38 P P N 
18 F 50 Cognitive symptoms 5 0.38 P N N 
19 F 37 Paresthesie in the tongue 
during neck retroflexion 
10 0.37 P N N 
20 F 45 Headache, Arthralgiae 1 0.36 N N N 
21 F 35 Conjuctivitis, Fatigue 5 0.43 P P N 
22 F 30 Seizures 1 0.33 N N N 
23 F 29 Aphthae 12 0.31 N N N 
24 F 45 Headache, Insomnia 1 0.29 N N N 
Pt. No – patient number, F – female, M – male, CSF – cerebrospinal fluid, OCB – 
oligoclonal bands, VEP – visual evoked potentials, ANA – antinuclear antibodies, N – 
negative, P – positive, ND – not done. CSF cell count /mm3; CSF proteins g/l. 
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Table 2. Results presented as % of patients with pathological results.  
 
 
CIS TN ON BS/C H M RIS 
p 
value 
Post hoc analysis* 
CSF cell count 40.9 37 46.7 45.3 11.1 24.5 16 0.031 NS 
CSF proteins 56.9 59.3 56 50 55.6 68.2 68 0.447 NS 
OCB 
 
82.4 82.4 72 81.3 66.7 77.3 44 0.002 
RIS vs. TN, ON, 
BS/C 
VEP 
 
43.8 41.2 67.8 43.3 62.5 53.8 14,3 0.001 
ON vs. TN, RIS 
RIS vs. ON, M 
ANA 14.7 17.6 13.3 17.2 0 11.4 16 0.701 NS 
 
TN – transverse myelitis, ON – optic neuritis, BS/C -  brainstem/cerebellar lesion, H - 
hemispheral symptoms, M – multifocal, RIS – radiologically isolated syndrome; CSF – 
cerebrospinal fluid, OCB – oligoclonal bands, VEP – visual evoked potentials, ANA – 
antinuclear antibodies. 
*significance calculated in post hoc analysis; NS – not significant 
